
GRAL
Healthcare · Diagnostics & Research · $5.21B market cap
$115.89-5.46 (-4.5%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +36.6% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2026 | After the close | -2.78 | -2.21 | +20.5% |
| Aug 5, 2026 | After the close | -2.91 | -2.56 | +12.0% |
| May 5, 2026 | After the close | -1.96 | -1.37 | +30.1% |
| Feb 19, 2026 | After the close | -2.53 | -2.44 | +3.6% |
| Nov 12, 2025 | After the close | -3.26 | -2.46 | +24.5% |
| Aug 12, 2025 | After the close | -3.56 | -3.18 | +10.7% |
| May 13, 2025 | After the close | -3.80 | -3.10 | +18.4% |
| Feb 20, 2025 | After the close | -4.97 | -2.89 | +41.9% |
| Nov 12, 2024 | After the close | -6.43 | -3.50 | +45.6% |
| Aug 13, 2024 | After the close | — | -51.06 | — |
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services,…